Mucin O‐Glycosylation and Mucolytic Therapies in Pseudomyxoma Peritonei: Literature Review
Medicinal Research Reviews · 2026-07 · 46 (4) · 1152-1172
DOI: 10.1002/med.70051 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 08.04.2026. Verfasst von Qi-Di Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Peritoneal Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing,…. Hauptthemen laut MEDLINE: Pseudomyxoma Peritonei, Mucins, Expectorants. Die Arbeit nennt 118 Literaturangaben.
Abstract (Originalsprache)
Effective mucolytic therapy can greatly improve the efficacy of cytoreductive surgery + hyperthermic intraperitoneal chemotherapy, alleviate symptoms and improve prognosis for pseudomyxoma peritonei (PMP) patients. The main components of PMP mucus are highly O‐glycosylated proteins called mucins. Represented by mucin2 (MUC2), mucins are the source of mucus viscoelasticity. This review investigated detailed processes of mucin O‐glycosylation and mucolytic therapies in PMP. We introduced molecular pathological mechanism of PMP, types of mucus and mucins in PMP, molecular structure and biological functions of mucins. We focus on the synthesis process and physiological functions of MUC2 O‐glycosylation. Furthermore, we summarize the potential therapeutic approaches to inhibiting mucin secretion and mucolysis. Detailed process of mucin O‐glycosylation in endoplasmic reticulum and Golgi apparatus was discussed. We discussed promising approaches to targeting the substrates and enzymes in O‐glycosylation, including uridine diphosphate and GalNAc analogs/derivatives, ppGalNAc‐T/GALNT inhibitors, disulfide bond reducing agents or PDI inhibitors, O‐glycosidases, and glucoproteinases. We provide a reference for the development of PMP mucolytic therapy, and some potential therapeutic targets aiming at mucin O‐glycosylation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Peritoneal Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
- Mucpharm Pty Ltd., Sydney, Australia.
- Department of Surgery, St George Hospital, Sydney, Australia.
- Interdisciplinary Research Group on Microscopic Imaging and Drug Development, Shenzhen Bay Laboratory, Shenzhen, China.
ORCID-Profile: Qi-Di Zhao, Yan Li
Zitieren
APA
Zhao, Q. D., Morris, D. L., Sun, Z. L., & Li, Y. (2026). Mucin O‐Glycosylation and Mucolytic Therapies in Pseudomyxoma Peritonei: Literature Review. Medicinal Research Reviews, 46(4), 1152-1172. https://doi.org/10.1002/med.70051
Vancouver
Zhao QD, Morris DL, Sun ZL, Li Y. Mucin O‐Glycosylation and Mucolytic Therapies in Pseudomyxoma Peritonei: Literature Review. Medicinal Research Reviews. 2026;46(4):1152-1172. doi:10.1002/med.70051
BibTeX
@article{Zhao2026,
author = {Zhao, Qi-Di and Morris, David L and Sun, Zheng-Long and Li, Yan},
title = {Mucin O‐Glycosylation and Mucolytic Therapies in Pseudomyxoma Peritonei: Literature Review},
journal = {Medicinal Research Reviews},
year = {2026},
volume = {46},
number = {4},
pages = {1152--1172},
doi = {10.1002/med.70051}
}
EUVIMED